菸鹼酸 Niacin × 皮膚健康

結論:證據支持但有警示

The skin-health evidence base does not concern niacin/nicotinic acid at all; it concerns oral nicotinamide, the separate amide form of vitamin B3.

C 🟠 C 薄弱證據 附警語發布 🚨 high — heavy affiliate marketing in TW community
⚠️ 標記 🇹🇼 台灣在地警示 💊 檢驗 / 藥物交互作用

The skin-health evidence base does not concern niacin/nicotinic acid at all; it concerns oral nicotinamide, the separate amide form of vitamin B3. The strongest study, the ONTRAC Phase 3 RCT (n=386), showed a 23% reduction in non-melanoma skin cancers, but only in immunocompetent patients with at least two prior NMSCs in the preceding 5 years, and the benefit vanished once the drug was stopped. The evidence is internally conflicting: the ONTRANS RCT in transplant recipients was null, the 2022 meta-analysis was positive while the stricter 2023 meta-analysis found no significant NMSC effect (RR 0.82, 95% CI 0.61-1.12). The AAD endorses oral nicotinamide only for a narrow high-risk subgroup (field cancerization or prior cSCC), explicitly not the general population, and Examine carries no skin outcome for niacin at all (L1 coverage gap). A grade of C reflects genuine but narrow and disputed benefit confined to a high-risk subgroup, with a serious risk that general consumers misread this as a broad skin-health benefit of niacin.

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.70
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 附警語發布
信心度
73%
證據方向大致一致
證據層級
E2
多篇高品質統合分析(≥2 篇一致)

各層「支持此療效」的程度

分數越低=該層越不支持
L1 Examine國際基準
0.50
L11 AI 複核獨立判讀
0.50
L3 機轉生理合理性
0.65
L5 臨床機構權威立場
0.72
L2 PubMed原始文獻
0.85
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.697
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — | B→C 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention (ONTRAC)
PMID: 26488693 2015 隨機對照試驗 n = 386
結論:In immunocompetent patients with at least two non-melanoma skin cancers in the prior 5 years, oral nicotinamide reduced the rate of new non-melanoma skin cancers by 23% vs placebo (95% CI 4 to 38, p=0.02); new basal-cell carcinomas were 20% lower and squamous-cell carcinomas 30% lower; actinic keratoses were 13% lower at 12 months. No benefit persisted after stopping the drug.
🟢 高品質 政府資助 效應量:Rate reduction 23% for NMSC; 20% BCC; 30% SCC
前往 PubMed
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients (ONTRANS)
PMID: 36856616 2023 隨機對照試驗 n = 158
結論:In immunosuppressed solid-organ transplant recipients with a prior history of keratinocyte cancers, oral nicotinamide did NOT reduce new keratinocyte cancers (207 in nicotinamide group vs 210 in placebo; rate ratio 1.0, 95% CI 0.8 to 1.3, p=0.96) nor actinic keratoses. The trial was terminated early due to low recruitment, limiting statistical power.
政府資助 效應量:Rate ratio 1.0 (no effect)
前往 PubMed
Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis
PMID: 35134311 2022 統合分析 n = 3,039
結論:Across 29 trials (3039 patients), nicotinamide was associated with a significant reduction in skin cancers vs control (rate ratio 0.50, 95% CI 0.29 to 0.85), with significant reductions in both BCC and cSCC, but an increased risk of digestive adverse effects.
效應量:Rate ratio 0.50 for skin cancer
前往 PubMed
The Role of Nicotinamide as Chemo-Preventive Agent in NMSCs: A Systematic Review and Meta-Analysis
PMID: 38201930 2023 統合分析
結論:Of 225 screened studies, four met inclusion criteria; the pooled analysis found no statistically significant association between oral nicotinamide and SCC (RR 0.81, 95% CI 0.48 to 1.37), BCC (RR 0.88, 95% CI 0.50 to 1.55) or NMSC overall (RR 0.82, 95% CI 0.61 to 1.12), concluding evidence is insufficient that oral nicotinamide significantly reduces keratinocyte cancers.
效應量:RR 0.82 NMSC (not significant)
前往 PubMed
Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin
PMID: 18492135 2004 隨機對照試驗
結論:Topical niacinamide significantly improved skin appearance, reducing fine lines, hyperpigmented spots, red blotchiness and skin sallowness vs vehicle control. Note: this is TOPICAL cosmetic use, distinct from the oral nicotinamide supplement claim assessed by this engine.
⚠️ 廠商資助 效應量:Significant improvement in multiple appearance endpoints
前往 PubMed

L4a US FDA
謹慎
the totality of the scientific evidence no longer supports the conclusion that a drug-induced reduction in triglyceride levels and/or increase in HDL-cholesterol levels in statin-treated patients results in a reduction in the risk of cardiovascular events 來源↗
L4b EU EFSA
中性
L4c UK NHS
謹慎
Taking high doses of nicotinic acid supplements can cause skin flushes. Taking high doses for a long time could lead to liver damage. ... Taking 17mg or less of nicotinic acid supplements a day, or 500mg or less of nicotinamide supplements a day, is unlikely to cause any harm. 來源↗
L4d TW TFDA / 衛福部
中性
菸鹼酸(包括菸鹼醯胺)屬第(八)類營養添加劑;用於錠狀、膠囊狀食品,每日食用限量以菸鹼素當量(N.E.)計不得超過 100 毫克。 來源↗
L4e WHO
中性
Pellagra is treated with at least 300 mg of nicotinamide in oral divided doses daily for 3-4 weeks. Nicotinamide is recommended in preference to nicotinic acid (niacin) because it does not cause the flushing reaction. 來源↗

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
中性
Niacin helps keep the nervous system, digestive system and skin healthy. 來源↗
L5c Cleveland Clinic
中性
L5d Harvard Health
支持
L5e Specialty Society (condition-mapped)
支持

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 極高
📍立場總覽

台灣社群對「B3 用於皮膚」聲量極高,但壓倒性集中在外用『菸鹼醯胺(niacinamide)』而非口服/外用的『菸鹼酸(niacin/nicotinic acid)』本尊。PTT BeautySalon、Dcard 美妝對外用菸鹼醯胺的共識:穩膚、控油、縮毛孔、退泛紅、淡黃氣有感,美白屬輔助而非主力,常被定位為『早C晚B』中和緩的調理成分。高濃度(如20%)或敏感肌可能泛紅刺癢,多人提醒從低濃度開始、與酸類分開使用。口服菸鹼酸(降血脂用)在皮膚脈絡幾無在地實測,僅以『niacin flush 臉紅潮紅』被提及。整體偏正面但屬個人經驗,且與本 intervention 的『酸型』非同一物。

💬社群實感

多數正面(外用菸鹼醯胺在穩膚、控油、縮毛孔、退泛紅、淡黃氣上多人有感;美白被視為輔助而非主力,少數敏感肌反映泛紅刺癢。口服菸鹼酸於護膚幾無在地實測)

破解迷思 社群最常見的 5 個誤解
迷思把『菸鹼醯胺(niacinamide,外用護膚的醯胺型)』與本 intervention『菸鹼酸(niacin/nicotinic acid,口服降血脂的酸型)』當成同一物
事實社群幾乎全在討論前者,兩者作用不同
迷思誤以為菸鹼醯胺『主打美白』
事實多數鄉民實測認為它強項是穩膚/控油/縮毛孔/退泛紅,美白屬輔助效果,效果不如直接的美白酸或傳明酸
迷思把外用後的泛紅刺癢直接當成『對菸鹼醯胺過敏』
事實多為血管擴張的 niacinamide flush(15~30分鐘內消退),常源自產品殘留菸鹼酸雜質或濃度過高,並非真正過敏
迷思誤以為『濃度越高越有效/越傷皮膚』
事實CIR 安全評估指 10% 以下長期使用不致刺激,泛紅程度與殘留菸鹼酸雜質量相關,而非濃度本身傷膚
迷思誤以為口服高劑量菸鹼酸能美白護膚
事實口服菸鹼酸是降血脂用途且會引發明顯潮紅(niacin flush),並非皮膚保健途徑
🩹 社群通報的副作用
  • 外用高濃度(如20%)或敏感肌出現臉頰泛紅、微熱、刺癢(多為菸鹼醯胺 flush,非過敏)
  • 與酸類(果酸/水楊酸/A醇)同時使用時刺激感、灼熱、發癢加重
  • 口服菸鹼酸高劑量的 niacin flush:臉部/胸頸潮紅、灼熱、刺癢(社群以降血脂脈絡提及,非護膚)
🏷️ 社群熱議品牌

依論壇被提及頻率,非銷售或品質排序。

  • 達特醫 Dr.Hsieh 菸鹼醯胺(低濃度藍款~20%高濃度,PTT/Dcard 最常被點名,業配亦多)
  • 理膚寶水 La Roche-Posay MELA B3/N10 抗斑精華(敏感肌友善常見推薦)
  • The Ordinary 菸鹼醯胺10%+鋅1%(平價熱門,含鋅對部分人偏刺激)
  • Olay 高效肌底/ProX 美白系列(含菸鹼醯胺,開架熱議)
  • Aveeno 含菸鹼醯胺保濕乳(WomenTalk/美妝版被提及)

⚠️ 列出僅代表「TW 社群討論度高」,不代表本站推薦或背書。本站不販售任何產品、無導購連結。

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

綜合維生素B群,包含B1、B2、B3、B5、B12、B9,長效持續8小時

代表來源 ↗
L10b · TFDA 法定身份 官方認定
💊藥品(須醫師處方/指示)

菸鹼素每日攝取量上限為100毫克菸鹼素當量;含維生素或礦物質之口服藥品基準表中,菸鹼素每日量逾35毫克NE且宣稱療效者列為指示藥品

來源 ↗

  • 每日防曬(廣效、SPF 30 以上)
  • 規律保濕與溫和清潔
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 5 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v25 engine_version: v1.0 claim_id: CLM-COND-skin-health-INT-niacin-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-skin-health-INT-niacin-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "菸鹼酸能改善皮膚健康",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 2,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟠 C 薄弱證據"
  }
}